Loading...
4536
XJPX
Market cap4.06bUSD
Nov 20, Last price  
2,002.00JPY
1D
-2.70%
1Q
6.52%
Jan 2017
40.00%
Name

Santen Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XJPX:4536 chart
P/E
17.24
P/S
2.21
EPS
116.13
Vol. 1Y
29.96%
Shs. 5Y
-3.89%
Rev. 5Y
3.16%
Div Yld LY
1.90%
Div Yld TTM
2.00%
Revenues
291.62b
-2.79%
100,485,000,000103,394,000,000101,618,000,000110,594,000,000110,812,000,000114,416,000,000119,066,000,000146,260,000,000161,831,000,000195,291,000,000199,096,000,000224,942,000,000234,026,000,000241,555,000,000249,605,000,000266,257,000,000279,037,000,000301,965,000,000300,004,000,000291,624,000,000
Net income
37.37b
+3.07%
13,147,000,00012,650,000,00010,123,000,00018,722,000,00021,333,000,00017,160,000,00016,520,000,00019,718,000,00024,032,000,00053,373,000,00021,717,000,00035,247,000,00031,954,000,00023,618,000,0009,311,000,00027,218,000,000-14,948,000,00026,643,000,00036,256,000,00037,369,000,000
CFO
43.50b
-28.60%
14,959,000,00015,468,000,00011,849,000,00026,110,000,00017,769,000,00021,483,000,0009,942,000,00026,686,000,00025,386,000,00022,525,000,00010,843,000,00042,843,000,00032,894,000,00039,947,000,00038,808,000,00046,043,000,00037,147,000,00072,649,000,00060,928,000,00043,500,000,000
Dividend
Mar 30, 202721 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.

Related entities

Subsidiaries (2)
Santen Oy
SANTEN PHARMACEUTICAL SPAIN SL

Key people

Rie Nakajima
Chief Operating Officer, Executive Officer, Director · since 2024
Kazuo Koshiji
Chief Financial Officer, Chief Risk Officer, Executive Officer · since 2022
Mika Masunari
Chief Compliance Officer, Executive Officer, General Counsel · since 2022
Shinichi Teramachi
Executive Officer, Director of Japan Business Ophthalmology Business, Senior Director in Main Sales Supervision Unit · since 2024
Fumiyasu Ako
Executive Officer · since 2023
Mark Dawson
Executive Officer, Chief Product Supply Officer · since 2023
Reza Haque
Executive Officer, Manager of Ophthalmology Innovation Center · since 2022
Ippei Kurihara
Executive Officer, Director · since 2024
Takahiro Morita
Executive Officer, Global Head of Sustainability · since 2021
Daisuke Nakata
Executive Officer, Chief Digital & Information Officer · since 2025
Marianthi Psacha
Executive Officer · since 2023
Yoko Saiki
Executive Officer · since 2023
Peter Sallstig
Executive Officer, Chief Medical Officer · since 2022
Yoshinori Watanabe
Executive Officer, Director of Japan Business Pharmaceutical Cosmetics Division · since 2023
Shawn Xiang
Executive Officer · since 2024
Tomoyuki Yoshida
Executive Officer · since 2024
Takeshi Ito
President, Chief Executive Officer, Representative Director · since 2022
Masahiko Ikaga
Independent Director · since 2024
Minoru Kikuoka
Independent Director · since 2024
IPO date
Nov 04, 1963
Employees
4,144
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
大深町4番20号
大阪府 大阪市北区 530-8552
JP
Address
4-20, Ofuka-cho
Kita-ku, Osaka-shi Osaka 530-8552
JP
Other language
Santen Pharmaceutical Co., Ltd.

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT